Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D3VF
|
|||
| Former ID |
DNC006709
|
|||
| Drug Name |
Ac-ICV(5fW)QDWGAHRCT-NH2
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C70H100FN21O18S2
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)OC)NC(=O)C(CS)NC(=O)C(C(C)C)NC(=O)C(CC1=CNC2=C1C=C(C=C2)F)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)C(C)NC(=O)C(CC5=CNC=N5)NC(=O)C(CCCN=C(N)N)NC(=O)C(CS)NC(=O)C(C(C)O)N
|
|||
| InChI |
1S/C70H100FN21O18S2/c1-8-33(4)57(69(109)110-7)92-66(106)51(30-112)90-68(108)56(32(2)3)91-64(104)47(21-37-26-79-43-16-15-38(71)22-41(37)43)86-60(100)45(17-18-52(72)94)85-63(103)49(24-54(96)97)88-62(102)46(20-36-25-78-42-13-10-9-12-40(36)42)83-53(95)28-80-58(98)34(5)82-61(101)48(23-39-27-76-31-81-39)87-59(99)44(14-11-19-77-70(74)75)84-65(105)50(29-111)89-67(107)55(73)35(6)93/h9-10,12-13,15-16,22,25-27,31-35,44-51,55-57,78-79,93,111-112H,8,11,14,17-21,23-24,28-30,73H2,1-7H3,(H2,72,94)(H,76,81)(H,80,98)(H,82,101)(H,83,95)(H,84,105)(H,85,103)(H,86,100)(H,87,99)(H,88,102)(H,89,107)(H,90,108)(H,91,104)(H,92,106)(H,96,97)(H4,74,75,77)/t33?,34-,35+,44-,45-,46-,47-,48-,49-,50-,51-,55-,56-,57-/m0/s1
|
|||
| InChIKey |
LNBPPCFNDRANJB-IIMWSTDNSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.